Gene: DLL1

28514
DELTA1|DL1|Delta
delta like canonical Notch ligand 1
protein-coding
6q27
Ensembl:ENSG00000198719 MIM:606582 Vega:OTTHUMG00000016078 UniprotKB:O00548
NG_027940.1
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.471e-1 (AD)  5.411e-2 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TRAF40.826
PLXNB10.806
RAPGEF30.801
ZHX20.8
CASKIN20.794
DPF30.768
DDR10.767
TOB20.766
CYP27A10.755
PHLPP10.753

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KCNH5-0.443
KCNH7-0.427
HS6ST3-0.422
SERTM1-0.418
TRPC5-0.414
SLC16A7-0.412
CNTN5-0.412
FREM3-0.411
TYRP1-0.411
COL19A1-0.407

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0493251,2-dithiol-3-thione"1,2-dithiol-3-thione results in increased expression of DLL1 mRNA"19162173
C5486512-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of DLL1 mRNA19933214
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C517041(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)"(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II) results in increased expression of DLL1 mRNA"19561079
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C014949acetylhydrazineacetylhydrazine results in decreased expression of DLL1 mRNA15282401
D020106AcrylamideAcrylamide results in decreased expression of DLL1 mRNA28959563
D000447AldehydesAldehydes results in increased expression of DLL1 mRNA25014914
C011512alpha-naphthoflavonealpha-naphthoflavone inhibits the reaction [Methylcholanthrene results in increased expression of DLL1 mRNA]29094188
D000643Ammonium ChlorideAmmonium Chloride affects the expression of DLL1 mRNA16483693
D001151ArsenicArsenic results in increased expression of DLL1 mRNA24019935
D001280AtrazineAtrazine results in increased expression of DLL1 mRNA18585445
D001554BenzeneBenzene results in increased expression of DLL1 mRNA19162166
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of DLL1 mRNA22316170
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased mutagenesis of DLL1 gene25435355
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of DLL1 mRNA19770486|2222880
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of DLL1 mRNA22300585
D004958EstradiolEstradiol results in increased expression of DLL1 mRNA25210133
C006780bisphenol Abisphenol A results in decreased expression of DLL1 mRNA25181051
C018475butyraldehydebutyraldehyde results in increased expression of DLL1 mRNA26079696
D002104CadmiumCadmium results in increased expression of DLL1 mRNA21120746
D000074262Canola OilCanola Oil metabolite results in increased expression of DLL1 mRNA27363782
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of DLL1 mRNA26272509
D003300Copper[Disulfiram binds to Copper] which results in decreased expression of DLL1 mRNA24690739
D003300CopperCopper results in decreased expression of DLL1 mRNA18522721
D019327Copper SulfateCopper Sulfate affects the expression of DLL1 mRNA19549813
C014347decitabinedecitabine affects the expression of DLL1 mRNA23300844
D002945CisplatinCisplatin affects the expression of DLL1 mRNA23300844
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of DLL1 mRNA26924002
D004041Dietary FatsDietary Fats results in increased expression of DLL1 mRNA18042831
D004221Disulfiram[Disulfiram binds to Copper] which results in decreased expression of DLL1 mRNA24690739
C118739entinostatentinostat results in decreased expression of DLL1 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
D005419FlavonoidsFlavonoids results in decreased expression of DLL1 mRNA18035473
C069837fullerene C60fullerene C60 results in decreased expression of DLL1 mRNA19167457
C039281furanfuran results in increased expression of DLL1 mRNA24183702
C039281furanfuran results in decreased expression of DLL1 mRNA25539665
D017313FenretinideFenretinide results in increased expression of DLL1 mRNA28973697
C029424hydrazinehydrazine results in decreased expression of DLL1 mRNA15282401
C492448ICG 001ICG 001 results in increased expression of DLL1 mRNA26191083
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of DLL1 mRNA25613284
D008044LinuronLinuron results in increased expression of DLL1 mRNA12730624
D008070LipopolysaccharidesLipopolysaccharides results in decreased expression of DLL1 mRNA18449946
D008344Maneb[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA23017109
C042720mercuric bromidemercuric bromide results in decreased expression of DLL1 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
D008727MethotrexateMethotrexate affects the expression of DLL1 mRNA18502557
D008748Methylcholanthrenealpha-naphthoflavone inhibits the reaction [Methylcholanthrene results in increased expression of DLL1 mRNA]29094188
D008748MethylcholanthreneMethylcholanthrene results in increased expression of DLL1 mRNA29094188
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of DLL1 mRNA23103053
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of DLL1 mRNA28001369
C004925methylmercuric chloridemethylmercuric chloride affects the expression of DLL1 mRNA20864626
C517284monomethyl phthalatemonomethyl phthalate affects the expression of DLL1 mRNA26924002
C523799MRK 003MRK 003 results in increased expression of DLL1 mRNA21169257
D009151Mustard GasMustard Gas results in decreased expression of DLL1 mRNA25102026
D037742Nanotubes, Carbon"Nanotubes, Carbon analog affects the expression of DLL1 mRNA"25554681
C031721naphthalenenaphthalene results in increased expression of DLL1 mRNA18978301
C007350nitrofennitrofen results in increased expression of DLL1 mRNA17618886
D009966OrphenadrineOrphenadrine affects the expression of DLL1 mRNA23665939
D010100OxygenOxygen deficiency results in increased expression of DLL1 mRNA25596134
D010100OxygenOxygen deficiency results in increased expression of DLL1 mRNA24223152
D010100OxygenOxygen deficiency results in increased expression of DLL1 mRNA24223152
D010100OxygenOxygen deficiency results in increased expression of DLL1 protein24223152
D000073878Palm OilPalm Oil results in increased expression of DLL1 mRNA18042831
D010269Paraquat[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA23017109
D010416PentachlorophenolPentachlorophenol results in increased expression of DLL1 mRNA23892564
C046012pentanalpentanal results in increased expression of DLL1 mRNA26079696
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of DLL1 mRNA26272509
C006253pirinixic acidpirinixic acid results in decreased expression of DLL1 mRNA23811191
D010938Plant OilsPlant Oils results in increased expression of DLL1 mRNA23370395
D011285Pregnenolone CarbonitrilePregnenolone Carbonitrile results in increased expression of DLL1 mRNA28903501
C005556propionaldehydepropionaldehyde results in increased expression of DLL1 mRNA26079696
D011441PropylthiouracilPropylthiouracil results in increased expression of DLL1 mRNA24780913
D053260SootSoot results in increased expression of DLL1 mRNA26551751
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of DLL1 mRNA22298810
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of DLL1 mRNA17517823|2290382
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of DLL1 mRNA28922406
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of DLL1 mRNA19933214
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of DLL1 mRNA25613284
C009495titanium dioxidetitanium dioxide affects the expression of DLL1 mRNA17656681
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased expression of DLL1 mRNA27404394
D014212TretinoinTretinoin results in decreased expression of DLL1 mRNA21934132
D014241TrichloroethylenePPARA protein inhibits the reaction [Trichloroethylene results in increased expression of DLL1 protein]15363585
D014241TrichloroethyleneTrichloroethylene results in increased expression of DLL1 mRNA15363585
D014241TrichloroethyleneTrichloroethylene results in increased methylation of DLL1 gene27618143
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of DLL1 mRNA24935251|2627250
C012589trichostatin Atrichostatin A results in increased expression of DLL1 mRNA24935251
D014520UrethaneUrethane results in decreased expression of DLL1 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of DLL1 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of DLL1 mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in increased methylation of DLL1 gene29154799
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of DLL1 gene25560391
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLL1 mRNA"27188386
C111237vorinostatvorinostat results in decreased expression of DLL1 mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005112Notch binding-IPI10079256  11006133  11823422  
GO:0005509calcium ion binding-IEA-  
GO:0005515protein binding-IPI10079256  11823422  15509766  24025447  
GO:0030957Tat protein binding-IPI15509766  
GO:0097110scaffold protein binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0001709cell fate determination-NAS11581320  
GO:0001756somitogenesis-ISS-  
GO:0001757somite specification-IEA-  
GO:0001947heart looping-ISS-  
GO:0002315marginal zone B cell differentiation-ISS-  
GO:0003323type B pancreatic cell development-ISS-  
GO:0007219Notch signaling pathway-IMP19682396  
GO:0007219Notch signaling pathway-ISS-  
GO:0007219Notch signaling pathway-NAS10079256  
GO:0007219Notch signaling pathway-TAS-  
GO:0007368determination of left/right symmetry-ISS-  
GO:0007386compartment pattern specification-IEA-  
GO:0008217regulation of blood pressure-ISS-  
GO:0008284positive regulation of cell proliferation-ISS-  
GO:0008285negative regulation of cell proliferation-ISS-  
GO:0009954proximal/distal pattern formation-ISS-  
GO:0014002astrocyte development-ISS-  
GO:0014807regulation of somitogenesis-ISS-  
GO:0021510spinal cord development-ISS-  
GO:0021688cerebellar molecular layer formation-ISS-  
GO:0021693cerebellar Purkinje cell layer structural organization-ISS-  
GO:0030097hemopoiesis-NAS11581320  
GO:0030154cell differentiation-TAS11912004  
GO:0030155regulation of cell adhesion-TAS11912004  
GO:0030857negative regulation of epithelial cell differentiation-ISS-  
GO:0032693negative regulation of interleukin-10 production-IMP23086448  
GO:0034351negative regulation of glial cell apoptotic process-ISS-  
GO:0035265organ growth-ISS-  
GO:0040008regulation of growth-ISS-  
GO:0045596negative regulation of cell differentiation-ISS-  
GO:0045605negative regulation of epidermal cell differentiation-ISS-  
GO:0045608negative regulation of inner ear auditory receptor cell differentiation-IEA-  
GO:0045638negative regulation of myeloid cell differentiation-IEA-  
GO:0045662negative regulation of myoblast differentiation-ISS-  
GO:0045665negative regulation of neuron differentiation-ISS-  
GO:0045747positive regulation of Notch signaling pathway-ISS-  
GO:0045807positive regulation of endocytosis-ISS-  
GO:0045944positive regulation of transcription by RNA polymerase II-ISS-  
GO:0046331lateral inhibition-ISS-  
GO:0048630skeletal muscle tissue growth-ISS-  
GO:0048631regulation of skeletal muscle tissue growth-ISS-  
GO:0048633positive regulation of skeletal muscle tissue growth-ISS-  
GO:0048665neuron fate specification-ISS-  
GO:0048839inner ear development-IEA-  
GO:0050767regulation of neurogenesis-ISS-  
GO:0051302regulation of cell division-ISS-  
GO:0060041retina development in camera-type eye-ISS-  
GO:0060042retina morphogenesis in camera-type eye-ISS-  
GO:0060853Notch signaling pathway involved in arterial endothelial cell fate commitment-ISS-  
GO:0070986left/right axis specification-IEA-  
GO:0072006nephron development-ISS-  
GO:0072014proximal tubule development-IEA-  
GO:0072070loop of Henle development-IEA-  
GO:0072583clathrin-dependent endocytosis-ISS-  
GO:0097009energy homeostasis-ISS-  
GO:0097102endothelial tip cell fate specification-ISS-  
GO:0097150neuronal stem cell population maintenance-IEP19682396  
GO:0097150neuronal stem cell population maintenance-ISS-  
GO:0098773skin epidermis development-ISS-  
GO:1900746regulation of vascular endothelial growth factor signaling pathway-ISS-  
GO:1903672positive regulation of sprouting angiogenesis-ISS-  
GO:2000726negative regulation of cardiac muscle cell differentiation-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-NAS11823422  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-NAS10079256  
GO:0005912adherens junction-ISS-  
GO:0016324apical plasma membrane-ISS-  
GO:0031410cytoplasmic vesicle-IEA-  
GO:0045121membrane raft-ISS-  
KEGG ID KEGG Term
hsa04330Notch signaling pathway
Reactome ID Reactome Term Evidence
R-HSA-157118Signaling by NOTCHIEA
R-HSA-157118Signaling by NOTCHTAS
R-HSA-162582Signal TransductionIEA
R-HSA-162582Signal TransductionTAS
R-HSA-1643685DiseaseTAS
R-HSA-1980143Signaling by NOTCH1IEA
R-HSA-1980145Signaling by NOTCH2IEA
R-HSA-1980150Signaling by NOTCH4TAS
R-HSA-2122948Activated NOTCH1 Transmits Signal to the NucleusIEA
R-HSA-2644602Signaling by NOTCH1 PEST Domain Mutants in CancerTAS
R-HSA-2644603Signaling by NOTCH1 in CancerTAS
R-HSA-2644606Constitutive Signaling by NOTCH1 PEST Domain MutantsTAS
R-HSA-2660825Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation MutantTAS
R-HSA-2660826Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation MutantTAS
R-HSA-2691230Signaling by NOTCH1 HD Domain Mutants in CancerTAS
R-HSA-2691232Constitutive Signaling by NOTCH1 HD Domain MutantsTAS
R-HSA-2894858Signaling by NOTCH1 HD+PEST Domain Mutants in CancerTAS
R-HSA-2894862Constitutive Signaling by NOTCH1 HD+PEST Domain MutantsTAS
R-HSA-2979096NOTCH2 Activation and Transmission of Signal to the NucleusIEA
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-9012852Signaling by NOTCH3IEA
R-HSA-9012852Signaling by NOTCH3TAS
R-HSA-9013507NOTCH3 Activation and Transmission of Signal to the NucleusIEA
R-HSA-9013507NOTCH3 Activation and Transmission of Signal to the NucleusTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25962154Downregulation of notch signaling pathway in late preterm and term placentas from pregnancies complicated by preeclampsia. (2015)Fragkiadaki PPLoS One
19106307Down-regulation of the notch pathway in human airway epithelium in association with smoking and chronic obstructive pulmonary disease. (2009 Mar 15)Tilley AEAm J Respir Crit Care Med